BiotechTube

rituximab + CHOP

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AIDS Related Lymphoma

Conditions

AIDS Related Lymphoma

Trial Timeline

Jan 1, 1999 → Oct 1, 2003

NCT ID
NCT00126243

About rituximab + CHOP

rituximab + CHOP is a phase 2 stage product being developed by Roche for AIDS Related Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00126243. Target conditions include AIDS Related Lymphoma.

What happened to similar drugs?

4 of 11 similar drugs in AIDS Related Lymphoma were approved

Approved (4) Terminated (1) Active (7)
✅TruvadaGilead SciencesApproved
✅bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)Gilead SciencesApproved
✅Emtricitabine and TenofovirGilead SciencesApproved
✅Maraviroc + Vardenafil + Maraviroc + PlaceboPfizerApproved
🔄EsomeprazoleAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3
🔄Recombinant Human Papillomavirus Nonavalent VaccineMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00126243Phase 2Terminated

Competing Products

20 competing products in AIDS Related Lymphoma

See all competitors
ProductCompanyStageHype Score
EsomeprazoleAstraZenecaPhase 3
40
EsomeprazoleAstraZenecaPhase 3
40
SelumetinibAstraZenecaPhase 1/2
24
MetforminMerckPhase 2/3
34
Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose) + Comparator: placeboMerckPhase 2
27
Recombinant Human Papillomavirus Nonavalent VaccineMerckPhase 3
40
R-EPOCH and cARTRochePhase 2
35
Elvitegravir, Cobicistat, TAF, FTC + Efavirenz, TDF, and 3TCGilead SciencesPre-clinical
18
Switch to E/C/FTC/TAF dailyGilead SciencesPhase 1/2
32
Biktarvy + SymtuzaGilead SciencesPhase 3
40
TruvadaGilead SciencesApproved
43
ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOSGilead SciencesPhase 2/3
42
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART)Gilead SciencesApproved
35
ChAdOx1.HTI + MVA.HTI + GS-9620 + Placebo + Placebo Oral TabletGilead SciencesPhase 2
35
E/C/F/TAF + E/C/F/TAF (Low Dose)Gilead SciencesPhase 2/3
38
EVG + Background regimenGilead SciencesPhase 2/3
30
Emtricitabine and TenofovirGilead SciencesApproved
39
TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tabletsGilead SciencesPhase 3
47
MaravirocPfizerPhase 1
29
Maraviroc + Vardenafil + Maraviroc + PlaceboPfizerApproved
43